Drug Repurposing During The COVID-19 Pandemic: Lessons For Expediting Drug Development And Access-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Drug Repurposing During The COVID-19 Pandemic: Lessons For Expediting Drug Development And Access

Published:2023-03-01 Issue:3 Volume:42 Page:424-432
ISSN:0278-2715
Container-title:Health Affairs
language:en
Short-container-title:Health Affairs

Author:

Greenblatt Wesley¹,Gupta Charu²,Kao Jennifer³

Affiliation:

1. Wesley Greenblatt, Harvard University, Boston Children’s Hospital, and Massachusetts Institute of Technology, Boston, Massachusetts.

2. Charu Gupta, University of California Los Angeles, Los Angeles, California.

3. Jennifer Kao (), University of California Los Angeles.

Publisher

Health Affairs (Project Hope)

Subject

Health Policy

Reference32 articles.

1. Existing FDA Pathways Have Potential To Ensure Early Access To, And Appropriate Use Of, Specialty Drugs

2. The COVID-19 Innovation System

3. Estimating The Cost Of New Drug Development: Is It Really $802 Million?

4. Innovation in the pharmaceutical industry: New estimates of R&D costs

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. COVID-19 therapeutics;Clinical Microbiology Reviews;2024-06-13

2. How health technology assessment can help to address challenges in drug repurposing: a conceptual framework;Drug Discovery Today;2024-06

3. Evaluating fluvoxamine for the outpatient treatment of COVID‐19: A systematic review and meta‐analysis;Reviews in Medical Virology;2023-12-26

4. Exogenous shocks and MNEs: Learning from pandemics, conflicts, and other major disruptions;Journal of World Business;2023-10

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP